BCTX
NASD BriaCell Therapeutics Corp$3.91 ↑ +0.00 (+0.00%) Trading Up from the previous close of $3.91, $0.09 below the day’s high of $4.00
- YTD change
- -45.01%
- vs 20-day SMA
- -2.72%
- vs 200-day SMA
- -5.57%
Price ranges
Price & Performance
-0.37 (-8.64%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.8% away from all-time highs of $1,870.50
- BCTX is down 45% since the beginning of the year
- BCTX is down 69% over the past 12 months
- BCTX is up 9% over the past 1 month
- 9% of all BCTX investors are betting against BCTX
BCTX reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -68.5%.
- Previous minute
- +$0.00
- Last hour
- -$0.03
- Last 5 days
- -4.87%
- vs 8-day SMA
- -4.14%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMTâ„¢ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.